{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T23:57:49Z","timestamp":1769644669654,"version":"3.49.0"},"reference-count":126,"publisher":"Rambam Health Corporation","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rambam Maimonides Med J"],"abstract":"<jats:p>Immunotherapy using immune checkpoint inhibitor (ICI) has been increasingly used in the oncology treatment field. Although ICIs could help suppress cancer and improve survival rates, it could also lead to certain adverse events, including immune-mediated liver injury caused by ICIs (ILICI). The manifestation of ILICI ranged greatly from asymptomatic disease to liver failure and even death. In this review article, we will discuss the pathogenesis, manifestation, and clinical approach of ILICI.<\/jats:p>","DOI":"10.5041\/rmmj.10571","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:17:48Z","timestamp":1769599068000},"page":"e0005","source":"Crossref","is-referenced-by-count":0,"title":["Immune Checkpoint Inhibitor-induced Hepatitis, an Emerging Issue in Precision Cancer Therapy Era: A Narrative Literature Review"],"prefix":"10.5041","volume":"17","author":[{"name":"Gastrointestinal Cancer Center, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-704X","authenticated-orcid":false,"given":"Randy","family":"Adiwinata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Tanadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fegita","family":"Pajala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Tandarto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Stella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffry","family":"Tenggara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Division of Hematology and Medical Oncology, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Gunarsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Gastrointestinal Cancer Center, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia; and Division of Hematology and Medical Oncology, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulus","family":"Simadibrata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Gastrointestinal Cancer Center, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianda","family":"Siregar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Gastrointestinal Cancer Center, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia; and Division of Gastroenterology and Hepatology, Department of Internal Medicine, Dharmais Cancer Hospital, Jakarta, Indonesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saut","family":"Nababan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Division of Hepatobiliary, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Budiman","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Gastrointestinal Cancer Center, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irsan","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Gastrointestinal Cancer Center, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia; and Division of Hepatobiliary, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosmas","family":"Lesmana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Gastrointestinal Cancer Center, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia; and Division of Hepatobiliary, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aru","family":"Sudoyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Gastrointestinal Cancer Center, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Division of Hematology and Medical Oncology, MRCCC Siloam Hospital Semanggi, Jakarta, Indonesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2983","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.3390\/jcm12134301","article-title":"Review of the immune checkpoint inhibitors in the context of cancer treatment","volume":"12","author":"Alturki","year":"2023","unstructured":"1. Alturki NA. Review of the immune checkpoint inhibitors in the context of cancer treatment. J Clin Med 2023;12:4301.","journal-title":"J Clin Med"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","unstructured":"2. Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol 2022;29:3044-60.","journal-title":"Curr Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.3390\/cancers15133490","article-title":"The effectiveness of cancer immune checkpoint inhibitor retreatment and rechallenge-a systematic review","volume":"15","author":"Perdyan","year":"2023","unstructured":"3. Perdyan A, Sobocki BK, Balihodzic A, D\u0105browska A, Kacperczyk J, Rutkowski J. The effectiveness of cancer immune checkpoint inhibitor retreatment and rechallenge-a systematic review. Cancers (Basel) 2023;15:3490.","journal-title":"Cancers (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2478\/rjim-2024-0015","article-title":"Immune checkpoint inhibitor colitis, a rising issue in targeted cancer therapy era: a literature review","volume":"62","author":"Adiwinata","year":"2024","unstructured":"4. Adiwinata R, Tandarto K, Tanadi C, et al. Immune checkpoint inhibitor colitis, a rising issue in targeted cancer therapy era: a literature review. Rom J Intern Med 2024;62:219-30.","journal-title":"Rom J Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"100719","DOI":"10.1016\/j.jhepr.2023.100719","article-title":"Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort","volume":"5","author":"Hountondji","year":"2023","unstructured":"5. Hountondji L, Ferreira De Matos C, Leboss\u00e9 F, et al. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Rep 2023;5: 100719.","journal-title":"JHEP Rep"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"102514","DOI":"10.1016\/j.jaut.2020.102514","article-title":"Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development","volume":"114","author":"Regev","year":"2020","unstructured":"6. Regev A, Avigan MI, Kiazand A, et al. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. J Autoimmun 2020;114:102514.","journal-title":"J Autoimmun"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.3748\/wjg.v27.i32.5376","article-title":"Immune checkpoint inhibitor-related hepatotoxicity: a review","volume":"27","author":"Remash","year":"2021","unstructured":"7. Remash D, Prince DS, McKenzie C, Strasser SI, Kao S, Liu K. Immune checkpoint inhibitor-related hepatotoxicity: a review. World J Gastroenterol 2021;27: 5376-91.","journal-title":"World J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. European Association for the Study of the Liver. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol 2019;70:1222-61.","DOI":"10.1016\/j.jhep.2019.02.014"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/hep.32689","article-title":"AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury","volume":"77","author":"Fontana","year":"2023","unstructured":"9. Fontana RJ, Liou I, Reuben A, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology 2023;77:1036-65.","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1077468","DOI":"10.3389\/fphar.2022.1077468","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: current updates and future perspectives","volume":"13","author":"Liu","year":"2022","unstructured":"10. Liu Z, Zhu Y, Xie H, Zou Z. Immune-mediated hepatitis induced by immune checkpoint inhibitors: current updates and future perspectives. Front Pharmacol 2022;13:1077468.","journal-title":"Front Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.rgmxen.2023.12.001","article-title":"Immune-mediated hepatitis: basic concepts and treatment","volume":"89","author":"Velarde-Ruiz Velasco","year":"2024","unstructured":"11. Velarde-Ruiz Velasco JA, Tapia Calder\u00f3n DK, Cerpa-Cruz S, et al. Immune-mediated hepatitis: basic concepts and treatment. Rev Gastroenterol Mex (Engl Ed) 2024;89:106-20.","journal-title":"Rev Gastroenterol Mex (Engl Ed)"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Zheng C, Huang S, Lin M, et al. Hepatotoxicity of immune checkpoint inhibitors: what is currently known. Hepatol Commun 2023;7:e0063.","DOI":"10.1097\/HC9.0000000000000063"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"907591","DOI":"10.3389\/fimmu.2022.907591","article-title":"Immune-mediated hepatitis during immune checkpoint inhibitor cancer immunotherapy: lessons from autoimmune hepatitis and liver immunology","volume":"13","author":"Hercun","year":"2022","unstructured":"13. Hercun J, Vincent C, Bilodeau M, Lapierre P. Immune-mediated hepatitis during immune checkpoint inhibitor cancer immunotherapy: lessons from autoimmune hepatitis and liver immunology. Front Immunol 2022;13:907591.","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"486","DOI":"10.14218\/JCTH.2021.00243","article-title":"Hepatotoxicity induced by biological agents: clinical features and current controversies","volume":"10","author":"Hernandez","year":"2022","unstructured":"14. Hernandez N, Bessone F. Hepatotoxicity induced by biological agents: clinical features and current controversies. J Clin Transl Hepatol 2022;10:486-95.","journal-title":"J Clin Transl Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.21037\/apm-23-250","article-title":"Management of autoimmune and viral hepatitis in immunotherapy: a narrative review","volume":"12","author":"Kuo","year":"2023","unstructured":"15. Kuo L, Kuwelker S, Tsai E. Management of autoimmune and viral hepatitis in immunotherapy: a narrative review. Ann Palliat Med 2023;12:1275-94.","journal-title":"Ann Palliat Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation","volume":"72","author":"Peeraphatdit","year":"2020","unstructured":"16. Peeraphatdit TB, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology 2020;72:315-29.","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Pham C, Ennin E, Enriquez K, et al. Immune-mediated liver injury from checkpoint inhibitors requiring supratherapeutic corticosteroid and mycophenolate treatment. AIM Clin Cases 2024;3: e230779.","DOI":"10.7326\/aimcc.2023.0779"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","unstructured":"18. Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5:95.","journal-title":"J Immunother Cancer"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Barry C, Huang J, Ubanatu CB, Bozym J. Delayed-onset immune-mediated hepatitis following pembrolizumab discontinuation: a case report. Cureus 2025; 17:e93926.","DOI":"10.7759\/cureus.93926"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Chopra M, Zhang HC. S3887 Recognition of delayed-onset immune checkpoint inhibitor-mediated hepatotoxicity treated with budesonide: a case study factoring in pharmacokinetics of immunotherapies. Am J Gastroenterol 2023;118(Suppl):S2481-2.","DOI":"10.14309\/01.ajg.0000965188.32051.39"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Echeverri-Hoyos J, Tuta-Quintero E, Echeverri Franco JA, Bonilla N, Rojas-Londo\u00f1o C. Late-onset immune-mediated hepatotoxicity induced by the immune checkpoint inhibitor pembrolizumab in lung cancer: a case report. Cureus 2025;17:e95961.","DOI":"10.7759\/cureus.95961"},{"key":"ref21","unstructured":"22. Lora DR, Post Z, Reau NS. Immune checkpoint inhibitor-related hepatitis: beyond the guidelines. World Gastroenterology Organisation 2025;3. Available at: https:\/\/www.worldgastroenterology.org\/publications\/e-wgn\/e-wgn-expert-point-of-view-articles-collection\/immune-checkpoint-inhibitor-related-hepatitis-beyond-the-guidelines (accessed December 31, 2025)."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cpt.2022.11.003","article-title":"Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: a systematic review","volume":"1","author":"Miao","year":"2022","unstructured":"23. Miao K, Zhang L. Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: a systematic review. Cancer Pathog Ther 2022;1:46-55.","journal-title":"Cancer Pathog Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.34172\/mejdd.2022.279","article-title":"Immune checkpoint inhibitors induced hepatotoxicity; gastroenterologists' perspectives","volume":"14","author":"Farshidpour","year":"2022","unstructured":"24. Farshidpour M, Hutson W. Immune checkpoint inhibitors induced hepatotoxicity; gastroenterologists' perspectives. Middle East J Dig Dis 2022;14:244-53.","journal-title":"Middle East J Dig Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1016\/j.apsb.2021.10.003","article-title":"Mechanisms of immune checkpoint inhibitor-mediated liver injury","volume":"11","author":"Shojaie","year":"2021","unstructured":"25. Shojaie L, Ali M, Iorga A, Dara L. Mechanisms of immune checkpoint inhibitor-mediated liver injury. Acta Pharm Sin B 2021;11:3727-39.","journal-title":"Acta Pharm Sin B"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","unstructured":"26. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:1856-67.","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","unstructured":"27. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390: 2461-71.","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10120-019-00970-8","article-title":"Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric\/gastroesophageal junction cancer","volume":"23","author":"Satoh","year":"2020","unstructured":"28. Satoh T, Kang YK, Chao Y, et al. Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric\/gastroesophageal junction cancer. Gastric Cancer 2020; 23:143-53.","journal-title":"Gastric Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","unstructured":"29. Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021;384:1191-203.","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial","volume":"36","author":"Larkin","year":"2018","unstructured":"30. Larkin J, Minor D, D'Angelo S, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol 2018;36:383-90.","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","article-title":"Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331\u2606","volume":"32","author":"Spigel","year":"2021","unstructured":"31. Spigel DR, Vicente D, Ciuleanu TE, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331\u2606. Ann Oncol 2021;32:631-41.","journal-title":"Ann Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","unstructured":"32. Andr\u00e9 T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020;383:2207-18.","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(24)00677-6","article-title":"Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial","volume":"26","author":"Chong","year":"2025","unstructured":"33. Chong WQ, Low JL, Tay JK, et al. Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial. Lancet Oncol 2025;26:175-86.","journal-title":"Lancet Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","unstructured":"34. Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020;396: 1817-28.","journal-title":"Lancet"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","unstructured":"35. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018;378:1789-801.","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","unstructured":"36. Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 2020; 38:193-202.","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1200\/JCO.19.03091","article-title":"Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer","volume":"38","author":"Galsky","year":"2020","unstructured":"37. Galsky MD, Mortazavi A, Milowsky MI, et al. Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer. J Clin Oncol 2020;38:1797-806.","journal-title":"J Clin Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","unstructured":"38. Kudo M, Ren Z, Guo Y, et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet 2025;405:203-15.","journal-title":"Lancet"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","unstructured":"39. Kuruvilla J, Ramchandren R, Santoro A, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2021; 22:512-24.","journal-title":"Lancet Oncol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","unstructured":"40. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016;17:1497-508.","journal-title":"Lancet Oncol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","unstructured":"41. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:1116-27.","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","unstructured":"42. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020;382:810-21.","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(22)00687-8","article-title":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF(V600) mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study","volume":"24","author":"Ascierto","year":"2023","unstructured":"43. Ascierto PA, Stroyakovskiy D, Gogas H, et al. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF(V600) mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. Lancet Oncol 2023;24:33-44.","journal-title":"Lancet Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1470-2045(23)00539-9","article-title":"Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study","volume":"25","author":"Bamias","year":"2024","unstructured":"44. Bamias A, Davis ID, Galsky MD, et al. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study. Lancet Oncol 2024;25:46-61.","journal-title":"Lancet Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","article-title":"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial","volume":"21","author":"Emens","year":"2020","unstructured":"45. Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol 2020;21:1283-95.","journal-title":"Lancet Oncol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","unstructured":"46. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894-905.","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(23)00540-5","article-title":"Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study","volume":"25","author":"Grande","year":"2024","unstructured":"47. Grande E, Arranz J, De Santis M, et al. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. Lancet Oncol 2024;25:29-45.","journal-title":"Lancet Oncol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","unstructured":"48. Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020;395:1835-44.","journal-title":"Lancet"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"49. Hida T, Kaji R, Satouchi M, et al. Atezolizumab in Japanese patients with previously treated advanced non-small-cell lung cancer: a subgroup analysis of the phase 3 OAK study. Clin Lung Cancer 2018;19:e405-15.","DOI":"10.1016\/j.cllc.2018.01.004"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","unstructured":"50. Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2022;23:995-1008.","journal-title":"Lancet Oncol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(24)00081-0","article-title":"Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study","volume":"25","author":"Kim","year":"2024","unstructured":"51. Kim S, Ghiringhelli F, de la Fouchardi\u00e8re C, et al. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study. Lancet Oncol 2024;25:518-28.","journal-title":"Lancet Oncol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.annonc.2019.10.021","article-title":"Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I\/III trial","volume":"31","author":"Mansfield","year":"2020","unstructured":"52. Mansfield AS, Ka\u017carnowicz A, Karaseva N, et al. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I\/III trial. Ann Oncol 2020;31:310-17.","journal-title":"Ann Oncol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","unstructured":"53. Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 2020;396:1090-100.","journal-title":"Lancet"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","unstructured":"54. Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:44-59.","journal-title":"Lancet Oncol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","unstructured":"55. Sangro B, Kudo M, Erinjeri JP, et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet 2025;405:216-32.","journal-title":"Lancet"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: Primary analysis of JAVELIN Gastric 300","volume":"29","author":"Bang","year":"2018","unstructured":"56. Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: Primary analysis of JAVELIN Gastric 300. Ann Oncol 2018;29:2052-60.","journal-title":"Ann Oncol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","unstructured":"57. Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 2021;22:450-62.","journal-title":"Lancet Oncol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","unstructured":"58. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:1103-15.","journal-title":"N Engl J Med"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","unstructured":"59. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015;16:522-30.","journal-title":"Lancet Oncol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","unstructured":"60. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.","journal-title":"N Engl J Med"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","unstructured":"61. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30: 2046-54.","journal-title":"J Clin Oncol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","unstructured":"62. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.","journal-title":"N Engl J Med"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","unstructured":"63. Maio M, Scherpereel A, Calabr\u00f2 L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol 2017;18:1261-73.","journal-title":"Lancet Oncol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1200\/JCO.2017.76.6212","article-title":"CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer","volume":"36","author":"Janjigian","year":"2018","unstructured":"64. Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 2018;36:2836-44.","journal-title":"J Clin Oncol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","unstructured":"65. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.","journal-title":"N Engl J Med"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"251","DOI":"10.14309\/ajg.0000000000000398","article-title":"Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors","volume":"115","author":"Miller","year":"2020","unstructured":"66. Miller ED, Abu-Sbeih H, Styskel B, et al. Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors. Am J Gastroenterol 2020;115:251-61.","journal-title":"Am J Gastroenterol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","unstructured":"67. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006-17.","journal-title":"N Engl J Med"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/ijc.30678","article-title":"Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data","volume":"141","author":"Wang","year":"2017","unstructured":"68. Wang W, Lie P, Guo M, He J. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data. Int J Cancer 2017;141:1018-28.","journal-title":"Int J Cancer"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"650292","DOI":"10.3389\/fonc.2021.650292","article-title":"Immune checkpoint inhibitor associated hepatotoxicity in primary liver cancer versus other cancers: a systematic review and meta-analysis","volume":"11","author":"Fu","year":"2021","unstructured":"69. Fu J, Li WZ, McGrath NA, et al. Immune checkpoint inhibitor associated hepatotoxicity in primary liver cancer versus other cancers: a systematic review and meta-analysis. Front Oncol 2021;11:650292.","journal-title":"Front Oncol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","unstructured":"70. Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2017;18:611-22.","journal-title":"Lancet Oncol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","unstructured":"71. Wang PF, Chen Y, Song SY, et al. Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol 2017;8:730.","journal-title":"Front Pharmacol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","unstructured":"72. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39.","journal-title":"N Engl J Med"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","unstructured":"73. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.","journal-title":"Lancet"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","unstructured":"74. Rizvi NA, Mazi\u00e8res J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16:257-65.","journal-title":"Lancet Oncol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","unstructured":"75. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30.","journal-title":"J Clin Oncol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","unstructured":"76. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375-84.","journal-title":"Lancet Oncol"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","unstructured":"77. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30.","journal-title":"N Engl J Med"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.jhepr.2023.100851","article-title":"Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: a 10-year real-world retrospective cohort study","volume":"5","author":"Atallah","year":"2023","unstructured":"78. Atallah E, Welsh SJ, O'Carrigan B, et al. Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: a 10-year real-world retrospective cohort study. JHEP Rep 2023;5:100851.","journal-title":"JHEP Rep"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1007\/s00432-022-04340-3","article-title":"Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival","volume":"149","author":"Miah","year":"2023","unstructured":"79. Miah A, Tinoco G, Zhao S, et al. Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. J Cancer Res Clin Oncol 2023;149:2235-42.","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1080\/14740338.2022.2134854","article-title":"Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"21","author":"Pan","year":"2022","unstructured":"80. Pan J, Liu Y, Guo X, et al. Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf 2022;21:1275-87.","journal-title":"Expert Opin Drug Saf"},{"key":"ref80","unstructured":"81. Keytruda FDA approval. Ireland: Merck Sharp & Dohme Corp; 2014. Available at: https:\/\/www.merck.com\/news\/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy\/ (accessed December 2, 2025)."},{"key":"ref81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jhep.2013.04.002","article-title":"Facing the dawn of immunotherapy for hepatocellular carcinoma","volume":"59","author":"MF","year":"2013","unstructured":"82. Sprinzl MF, Galle PR. Facing the dawn of immunotherapy for hepatocellular carcinoma. J Hepatol 2013;59:9-10.","journal-title":"J Hepatol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40425-014-0033-1","article-title":"Ipilimumab administration for advanced melanoma in patients with pre-existing hepatitis B or C infection: a multicenter, retrospective case series","volume":"2","author":"Ravi","year":"2014","unstructured":"83. Ravi S, Spencer K, Ruisi M, et al. Ipilimumab administration for advanced melanoma in patients with pre-existing hepatitis B or C infection: a multicenter, retrospective case series. J Immunother Cancer 2014; 2:33.","journal-title":"J Immunother Cancer"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","unstructured":"84. Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.","journal-title":"J Hepatol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals","volume":"168","author":"Ali","year":"2025","unstructured":"85. Ali FS, Nguyen MH, Hernaez R, et al. AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals. Gastroenterology 2025;168:267-84.","journal-title":"Gastroenterology"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.14309\/ajg.0000000000002361","article-title":"Immune checkpoint inhibitors suppress hepatitis C virus replication in infected patients with solid tumors","volume":"118","author":"Yibirin","year":"2023","unstructured":"86. Yibirin M, Mustafayev K, Hosry J, et al. Immune checkpoint inhibitors suppress hepatitis C virus replication in infected patients with solid tumors. Am J Gastroenterol 2023;118:1609-17.","journal-title":"Am J Gastroenterol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature","volume":"25","author":"Kumar","year":"2020","unstructured":"87. Kumar V, Shinagare AB, Rennke HG, et al. The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature. Oncologist 2020;25:505-14.","journal-title":"Oncologist"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/annonc\/mdx548","article-title":"Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient","volume":"29","author":"Biondani","year":"2018","unstructured":"88. Biondani P, De Martin E, Samuel D. Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient. Ann Oncol 2018;29:286-7.","journal-title":"Ann Oncol"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1053\/j.ackd.2016.08.002","article-title":"The bad and the good news on cancer immunotherapy: implications for organ transplant recipients","volume":"23","author":"Maggiore","year":"2016","unstructured":"89. Maggiore U, Pascual J. The bad and the good news on cancer immunotherapy: implications for organ transplant recipients. Adv Chronic Kidney Dis 2016;23: 312-16.","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1038\/ajg.2017.387","article-title":"Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma","volume":"112","author":"Varkaris","year":"2017","unstructured":"90. Varkaris A, Lewis DW, Nugent FW. Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma. Am J Gastroenterol 2017;112: 1895-6.","journal-title":"Am J Gastroenterol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","unstructured":"91. Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med 2018;168:121-30.","journal-title":"Ann Intern Med"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","unstructured":"92. Danlos FX, Voisin AL, Dyevre V, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer 2018;91:21-9.","journal-title":"Eur J Cancer"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00262-018-2134-z","article-title":"Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders","volume":"67","author":"K\u00e4hler","year":"2018","unstructured":"93. K\u00e4hler KC, Eigentler TK, Gesierich A, et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol Immunother 2018;67:825-34.","journal-title":"Cancer Immunol Immunother"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","unstructured":"94. Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017;28:368-76.","journal-title":"Ann Oncol"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","unstructured":"95. Tison A, Qu\u00e9r\u00e9 G, Misery L, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol 2019;71:2100-11.","journal-title":"Arthritis Rheumatol"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","unstructured":"96. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2016;2:234-40.","journal-title":"JAMA Oncol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejim.2021.10.035","article-title":"Drug-induced liver injury: pathogenesis, epidemiology, clinical features, and practical management","volume":"97","author":"Bj\u00f6rnsson","year":"2022","unstructured":"97. Bj\u00f6rnsson HK, Bj\u00f6rnsson ES. Drug-induced liver injury: pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med 2022;97:26-31.","journal-title":"Eur J Intern Med"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3748\/wjg.v24.i13.1373","article-title":"Dissecting the molecular pathophysiology of drug-induced liver injury","volume":"24","author":"Ye","year":"2018","unstructured":"98. Ye H, Nelson LJ, G\u00f3mez Del Moral M, Mart\u00ednez-Naves E, Cubero FJ. Dissecting the molecular pathophysiology of drug-induced liver injury. World J Gastroenterol 2018;24:1373-85.","journal-title":"World J Gastroenterol"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1053\/j.gastro.2013.12.032","article-title":"Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives","volume":"146","author":"Fontana","year":"2014","unstructured":"99. Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology 2014;146:914-28.","journal-title":"Gastroenterology"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"100704","DOI":"10.1016\/j.iotech.2024.100704","article-title":"Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities","volume":"21","author":"McKenzie","year":"2024","unstructured":"100. McKenzie J, Sneath E, Trinh A, Nolan M, Spain L. Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities. Immunooncol Technol 2024;21: 100704.","journal-title":"Immunooncol Technol"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/liv.13746","article-title":"Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents","volume":"38","author":"Suzman","year":"2018","unstructured":"101. Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int 2018;38:976-87.","journal-title":"Liver Int"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.crad.2017.04.003","article-title":"Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors","volume":"72","author":"Alessandrino","year":"2017","unstructured":"102. Alessandrino F, Tirumani SH, Krajewski KM, et al. Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. Clin Radiol 2017;72:521-33.","journal-title":"Clin Radiol"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","unstructured":"103. De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 2018;68:1181-90.","journal-title":"J Hepatol"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1111\/liv.14489","article-title":"Immune-related hepatitis related to checkpoint inhibitors: clinical and prognostic factors","volume":"40","author":"Riveiro-Barciela","year":"2020","unstructured":"104. Riveiro-Barciela M, Barreira-D\u00edaz A, Vidal-Gonz\u00e1lez J, et al. Immune-related hepatitis related to checkpoint inhibitors: clinical and prognostic factors. Liver Int 2020;40:1906-16.","journal-title":"Liver Int"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","unstructured":"105. Weber JS, K\u00e4hler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-7.","journal-title":"J Clin Oncol"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/COC.0000000000000374","article-title":"Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management","volume":"41","author":"Huffman","year":"2018","unstructured":"106. Huffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clin Oncol 2018;41:760-5.","journal-title":"Am J Clin Oncol"},{"key":"ref106","unstructured":"107. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. National Institutes of Health, National Cancer Institute; 2017. Available at: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf (accessed December 31, 2025)."},{"issue":"1","key":"ref107","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","article-title":"Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct","volume":"32","author":"Fontana","year":"2009","unstructured":"108. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009;32(1):55-68.","journal-title":"Drug Saf"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/cld.1241","article-title":"Immune checkpoint inhibitor-related liver toxicity","volume":"20","author":"Bolte","year":"2022","unstructured":"109. Bolte FJ, Hall RD, Shah NL. Immune checkpoint inhibitor-related liver toxicity. Clin Liver Dis (Hoboken) 2022;20:93-6.","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/liv.15340","article-title":"Immune checkpoint inhibitor-related cholangiopathy: novel clinicopathological description of a multi-centre cohort","volume":"43","author":"Berry","year":"2023","unstructured":"110. Berry P, Kotha S, Zen Y, et al. Immune checkpoint inhibitor-related cholangiopathy: novel clinicopathological description of a multi-centre cohort. Liver Int 2023;43:147-54.","journal-title":"Liver Int"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jtho.2020.09.007","article-title":"Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis","volume":"16","author":"Moi","year":"2021","unstructured":"111. Moi L, Bouchaab H, Mederos N, et al. Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis. J Thorac Oncol 2021;16:318-26.","journal-title":"J Thorac Oncol"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","article-title":"Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review","volume":"26","author":"Onoyama","year":"2020","unstructured":"112. Onoyama T, Takeda Y, Yamashita T, et al. Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review. World J Gastroenterol 2020;26:353-65.","journal-title":"World J Gastroenterol"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.2169\/internalmedicine.2330-18","article-title":"Successful treatment of nivolumab-related cholangitis with prednisolone: a case report and review of the literature","volume":"58","author":"Sawada","year":"2019","unstructured":"113. Sawada K, Shonaka T, Nishikawa Y, et al. Successful treatment of nivolumab-related cholangitis with prednisolone: a case report and review of the literature. Intern Med 2019;58:1747-52.","journal-title":"Intern Med"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"955","DOI":"10.37349\/etat.2024.00257","article-title":"Hepatobiliary complications of immune checkpoint inhibitors in cancer","volume":"5","author":"Zhuang","year":"2024","unstructured":"114. Zhuang D, Zhang D, Riordan S. Hepatobiliary complications of immune checkpoint inhibitors in cancer. Explor Target Antitumor Ther 2024;5:955-70.","journal-title":"Explor Target Antitumor Ther"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.4254\/wjh.v14.i7.1269","article-title":"Checkpoint inhibitor-induced hepatotoxicity: role of liver biopsy and management approach","volume":"14","author":"Bessone","year":"2022","unstructured":"115. Bessone F, Bjornsson ES. Checkpoint inhibitor-induced hepatotoxicity: role of liver biopsy and management approach. World J Hepatol 2022;14:1269-76.","journal-title":"World J Hepatol"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","unstructured":"116. Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology 2021;160: 1384-93.","journal-title":"Gastroenterology"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jamaoncol.2021.4342","article-title":"Utility of liver biopsy in diagnosis and management of high-grade immune checkpoint inhibitor hepatitis in patients with cancer","volume":"7","author":"Li","year":"2021","unstructured":"117. Li M, Sack JS, Bell P, et al. Utility of liver biopsy in diagnosis and management of high-grade immune checkpoint inhibitor hepatitis in patients with cancer. JAMA Oncol 2021;7:1711-14.","journal-title":"JAMA Oncol"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.3390\/jcm12113751","article-title":"Histological characteristics and management of hepatitis on immune checkpoint inhibitors: a retrospective descriptive study","volume":"12","author":"Parlati","year":"2023","unstructured":"118. Parlati L, Marcin K, Terris B, et al. Histological characteristics and management of hepatitis on immune checkpoint inhibitors: a retrospective descriptive study. J Clin Med 2023;12:3751.","journal-title":"J Clin Med"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","unstructured":"119. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 2021; 39:4073-126.","journal-title":"J Clin Oncol"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.62347\/QQEI5676","article-title":"Clinical significance of liver biopsy in the diagnosis of liver disease and the evaluation of the clinical efficacy of antiviral treatment for chronic hepatitis B","volume":"16","author":"Xie","year":"2024","unstructured":"120. Xie X, He X, Ye X, et al. Clinical significance of liver biopsy in the diagnosis of liver disease and the evaluation of the clinical efficacy of antiviral treatment for chronic hepatitis B. Am J Transl Res 2024;16:4867-75.","journal-title":"Am J Transl Res"},{"key":"ref120","unstructured":"121. Escobar D. Pathology pearls: immune checkpoint inhibitor hepatitis. 2021; September 19. Liver Fellow Network. Available at: https:\/\/www.aasld.org\/liver-fellow-network\/core-series\/pathology-pearls\/pathology-pearls-immune-checkpoint-inhibitor#:~:text=Immune%20Checkpoint%20Inhibitor%20(ICI)%20Hepatitis,-Immune%20checkpoint%20inhibitor&text=Adverse%20events%20in%20the%20gastrointestinal,evidence%20of%20mucositis%20and%20hepatitis (accessed December 31, 2025)."},{"key":"ref121","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/hepr.14078","article-title":"Diagnostic guide for immune checkpoint inhibitor-induced liver injury","volume":"54","author":"Ito","year":"2024","unstructured":"122. Ito T, Takeuchi Y, Mizuno K, et al. Diagnostic guide for immune checkpoint inhibitor-induced liver injury. Hepatol Res 2024;54:719-26.","journal-title":"Hepatol Res"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","unstructured":"123. Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33:1217-38.","journal-title":"Ann Oncol"},{"key":"ref123","doi-asserted-by":"publisher","unstructured":"124. Dougan M, Blidner AG, Choi J, et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the man-agement of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Support Care Cancer 2020;28:6129-43.","DOI":"10.1007\/s00520-020-05707-3"},{"key":"ref124","unstructured":"125. National Comprehensive Cancer Network. Management of immunotherapy-related toxicities. Version 1.2024. NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network; 2024. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1486 (accessed December 30, 2025)."},{"key":"ref125","doi-asserted-by":"publisher","unstructured":"126. Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021;9: e002435.","DOI":"10.1136\/jitc-2021-002435"}],"container-title":["Rambam Maimonides Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.rmmj.org.il\/userimages\/3867\/1\/PublishFiles\/4151Article.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:34:13Z","timestamp":1769600053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.rmmj.org.il\/issues\/69\/articles\/4151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":126,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,28]]}},"URL":"https:\/\/doi.org\/10.5041\/rmmj.10571","relation":{},"ISSN":["2076-9172"],"issn-type":[{"value":"2076-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}